The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...

Air pollution exposure is associated with an increased risk of developing Parkinson disease (PD) and dyskinesia, according to study results published in JAMA Network Open.

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

TUCSON, Ariz., November 13, 2024 — Critical Path Institute (C-Path) today announced a landmark initiative, Gender Equitable Medicines for Parkinson's Disease (GEM-PD), dedicated to globally advancing ...

Multilocus sequence typing analysis showed 24.7% of those with MAC-PD had a genetically different strain within the same species at least once in on-treatment isolates. A fourth of patients with ...

"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...